Zhi-Gang Sun, Zhi-Na Li and Hai-Liang Zhu* Pages 1 - 10 ( 10 )
Diabetes mellitus (DM) is a metabolic disease, and diabetes patients have long-term higher blood sugar levels than standard. Most people with diabetes have complications that greatly affect their standard of living. Patients with type 2 DM occupy the vast majority of all diabetes patients. Glucagon-like peptide-1 (GLP-1) secreted by intestinal enteroendocrine L-cells is a small molecule polypeptide, which is glucose concentration-dependent and can effectively reduce blood glucose concentration. Dipeptidyl peptidase-4 (DPP-4) is an important target for the treatment of type 2 DM because it can degrade GLP-1. DPP-4 inhibitors can enhance the blood glucose lowering effect of GLP-1 by inhibiting DPP-4. This article summarizes the development of DPP-4 inhibitors from 2015 to 2019, and can provide helpful information for the discovery of novel DPP-4 inhibitors in the future.
Research, DPP-4, Type 2 diabetes mellitus, Inhibitors, GLP-1, Progress
Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi 276400, Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi 276400, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Road, Nanjing 210023